Login Register Cart 0

Frontiers in Clinical Drug Research – Anti Allergy Agents

Volume: 5

Back Book Details

Aspirin Desensitization/Challenge in Patients with Cardiovascular Diseases: Current Trends and Advances

Author(s): Aysa Rezabakhsh and Hassan Soleimanpour *

Pp: 147-189 (43)

DOI: 10.2174/9789815040616122050007

* (Excluding Mailing and Handling)

Abstract

Aspirin, known as acetylsalicylic acid (ASA), is one of the most commonly
used medications. Available as over-the-counter medicine, ASA is prescribed as a
nonsteroidal anti-inflammatory and anti-platelet drug and has the potential to decrease
pain and fever. ASA is also considered as a first-line drug for the treatment of some
cardiovascular diseases such as coronary artery diseases (CAD) and myocardial
infarction (MI). Subsequently, it has been demonstrated to reduce the morbidity and
mortality rate of these diseases. Besides the beneficial effects, ASA has the potential to
provoke some allergic reactions, particularly in patients with CAD. According to
previous reports, in 1.5-2.6% of the subjects with CVD treated with ASA, aspirinexacerbated
respiratory disease or chronic idiopathic urticaria were observed. In this
book chapter, we aimed to summarize all-new achievements and novel findings of
recent clinical advances related to the desensitization approaches following aspirin
consumption in patients with CADs

Keywords: Acetylsalicylic Acid, Allergic Reactions, Anti-Platelet Effects, Antithrombotic effect, Aspirin (ASA), Aspirin Challenge, Aspirin Desensitization, Aspirin-Induced Exacerbated Respiratory Disease (AERD), Cardiovascular Disease (CVD), Clinical Advances, Clinical Trials, Coronary Artery Diseases (CAD), Cyclooxygenase (COX), Hypersensitivity, Leukotriene, Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Prostaglandins, Rapid Desensitization, Sensitivity, Slow Desensitization.

Cite as

Related Journals
View More
Related Books
View More
© 2024 Bentham Science Publishers | Privacy Policy